Rep. Diana Harshbarger

Maddy summaryThis bill would amend federal law to require the rejection of a state's electoral votes for president if a candidate nominated by a major political party did not appear on that state's ballot. It defines "major political party" using the IRS's criteria for "major party" status under the Internal Revenue Code. The change directly affects states' ability to certify presidential election results, as electoral votes from any state failing to include a major party candidate would be disqualified from counting. The bill does not alter voting procedures or ballot access but modifies the federal process for certifying electoral votes.

Maddy summaryHR 6853, the SOS Act, requires the Congressional Budget Office to include a new graph in annual reports about Social Security trust funds. The graph must compare projected payments under a 1985 law (section 257(b)(1)) with actual outlays from current law. This procedural bill affects how Congress reports on Social Security funding, adding transparency about payment assumptions versus current spending. It does not change eligibility or benefit amounts for seniors or disability recipients.

Maddy summaryThe WARM Act of 2023 creates a national menopause public awareness program through the CDC, allocating $70 million for 2025-2028 to increase understanding of menopause symptoms, related health conditions, and treatment options through culturally competent educational materials. It provides $31.7 million for grants to train health care providers (including physicians, nurses, and pharmacists) in managing menopausal symptoms, with priority given to institutions serving rural, Tribal, and other underserved communities. The bill also establishes regional centers of excellence to develop evidence-based curricula for health professions schools to improve menopause education. The program requires reports to Congress by 2025 and 2026 on implementation and effectiveness.

Maddy summaryThis bill reauthorizes and extends funding for programs addressing substance use disorders and opioid addiction, including residential treatment for pregnant and postpartum women, first responder training, and community recovery initiatives. It increases funding levels for these programs, adds xylazine to Schedule III of controlled substances, and requires a study on remote monitoring for patients prescribed opioids. The bill also expands Medicaid coverage requirements for medication-assisted treatment and mandates reporting on mental health condition data alongside substance use disorder data, directly affecting individuals with substance use disorders, healthcare providers, and state and tribal governments.

Maddy summaryThis bill bans federal funding for at-home COVID-19 tests manufactured in China, imported from China, or produced by Chinese subsidiaries. It directly affects government programs purchasing these tests, such as public health initiatives or emergency response efforts. The key provision prohibits all federal spending on such tests to prevent taxpayer dollars from supporting Chinese-manufactured products. The policy change is limited to specific test origins and does not alter broader public health funding rules.

Maddy summaryThe DEFUND Act of 2023 would end U.S. membership in the United Nations and all its affiliated bodies, including the World Health Organization. It repeals all U.S. participation laws, cuts all funding for UN contributions, closes the U.S. Mission to the UN, and requires the UN to vacate U.S. government property. The bill also revokes diplomatic immunity for UN personnel and prohibits future U.S. re-entry into the UN without explicit Senate approval. These provisions would fundamentally sever U.S. legal and financial ties to the United Nations system.

Maddy summaryThis bill creates a federal grant program to expand access to mental health care for rural residents and those working in farming, fishing, or forestry (Triple-F industry). It authorizes up to $10 million annually (2024-2028) for nonprofit or public organizations to deliver home-based telemental health services - using video or phone - directly to patients in their homes. The program specifically targets areas with health professional shortages or Triple-F workers, requiring grantees to measure service quality compared to in-person care. Reports on outcomes must be submitted to Congress after three years to evaluate effectiveness.

Maddy summaryHRES 870 is a symbolic House resolution supporting National Rural Health Day, observed annually on the third Thursday of November. It recognizes rural health care providers and the 60+ million people living in rural communities who face challenges like hospital closures, limited access to care, and health disparities. The resolution expresses commitment to improving rural health care accessibility and affordability but includes no new funding, programs, or policy changes - only a formal acknowledgment of existing efforts. It directly affects rural communities by honoring their health care contributions through a non-binding statement.

Maddy summaryHR 6504, the Protect American Gun Exporters Act, blocks the Department of Commerce from implementing a pause on new export licenses for specific firearm exports (items under Commerce Control List numbers 0A501, 0A502, 0A504, and 0A505). The bill directly affects U.S. gun exporters by preventing the Commerce Secretary from enforcing the October 2023 pause or similar restrictions on these exports. Key provisions prohibit the Secretary from taking any action to carry out the pause unless it follows standard regulatory processes, including a required impact analysis and compliance with the Administrative Procedure Act and Congressional Review Act. This bill does not create new export rules but stops the existing pause on certain firearm exports.

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023 This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.